Clinical trial
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
NCT00490516
Study timeline
Study start (unknown)2007-06-01Date precision: month
Registry last updated2025-01-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Schizophreniaunresolved
Interventions
Sponsors & collaborators
ACADIA Pharmaceuticals Inc.lead sponsor
Mapped research locations
PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1San DiegoCalifornia, United States1AustinTexas, United States1AnaheimCalifornia, United States1RiversideCalifornia, United States1GlendaleCalifornia, United States1PasadenaCalifornia, United States1BradentonFlorida, United States1Garden GroveCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00490516 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.